Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Alliance Pharma to delay release of 2023 results

(Sharecast News) - Shares in Alliance Pharma slipped on Friday after the healthcare company said that its full-year results would be delayed. Alliance, which had been due to publish its preliminary results for 2023 on 9 April, said figures are now expected to be released on 23 April.

"The group's auditor has determined that the volume of work required to complete the audit has exceeded its original expectations, necessitating a short delay in the reporting timetable," the statement said.

Nevertheless, the company assured that details provided in its latest trading update in January "remain accurate".

Alliance has already reported revenues of £182.7m for 2023, up 6% on the previous year, while underlying profits were said to be in line with market expectations.

The stock was down 2% at 37.66p by 0803 BST.

Share this article

Related Sharecast Articles

Goldman Sachs to scrap bonus cap for UK dealmakers
(Sharecast News) - Goldman Sachs will remove a cap on bonuses for its London-based staff, according to Sky News, with the firm now set to resume making multi-million-pound payouts to its top-performing traders and dealmakers.
Gazprom swings to $6.9bn loss as Europe sales plunge
(Sharecast News) - Russia's natural gas heavyweight Gazprom swung to huge loss in 2023 after sales to Europe dropped due to Western sanctions on Moscow.
London cabbies launch £250m legal action against Uber
(Sharecast News) - Uber Technologies is facing legal action on behalf of more than 10,500 London black cab drivers, it was confirmed on Thursday.
Peloton announces CEO departure; to cut 15% of workforce
(Sharecast News) - Peloton announced the departure of its chief executive on Thursday, alongside plans to cut around 15% of its workforce amid a restructuring programme aimed at reducing annual expenses by more than $200m.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.